Shows that canakinumab induces long-lasting inactive disease in juvenile patients, indicating a promising treatment option.
Canakinumab steroid-free first-line therapy in newly diagnosed sJIA induces long-lasting, drug-free inactive disease in a substantial proportion of patients. Discontinuation of canakinumab was associated with disease flares in a minority of patients.
No takes yet. Share an insight, caveat, or question.
Horneff et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: